Improvement of Comorbid Psoriasis in Patients With MS Treated With Natalizumab
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received August 14, 2020
- Accepted in final form December 8, 2020
- First Published February 15, 2021.
Author Disclosures
- Regina Berkovich, MD, PhD,
- Aida Yakupova, MD, PhD (aidayakupova{at}yandex.ru),
- Jonathan Eskenazi, MD (jeskena{at}hotmail.com),
- Noel G. Carlson, PhD (noel.carlson{at}va.gov) and
- Lawrence Steinman, MD (aidayakupova{at}yandex.ru)
- Regina Berkovich, MD, PhD,
(1)MSAA (2)NMSS (3)Biogen (4)Genentech (5)Novartis (6) Sanofi (7)Bayer (8)Mallinckrodt (9)Alexion (10) Celgene
NONE
Travel and Speaker honoraria received from Alexion, Bayer, Biogen, Celgene, Sanofi, Genentech, Mallinckrodt, Novartis,
Journal of Medical Case Reports - Associate Editor
NONE
NONE
Regina Berkovich MD, PhD Inc (2018-present) USC Keck School of Medicine USC Neurology (2004-2018) Teaching faculty for USC+LAC (2006-present)
NONE
Alexion, Biogen, Celgene, Sanofi, Novartis, Mallinckrodt
NONE
NONE
Biogen Sanofi Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Aida Yakupova, MD, PhD (aidayakupova{at}yandex.ru),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jonathan Eskenazi, MD (jeskena{at}hotmail.com),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Noel G. Carlson, PhD (noel.carlson{at}va.gov) and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I am employed by the Department of Veterans Affairs and the University of Utah.
NONE
I have received research support from: Biogen and Astra Zeneca.
I have received funding from The Department of Veterans Affairs Merit Review.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lawrence Steinman, MD (aidayakupova{at}yandex.ru)
Novartis, Atreca, Bristol Myers Squibb, Gossamer, 180LS, TG Therapeutics, Atara Bio
NONE
Novartis, Atara Bio
MS Journal, Proceedings National Academy of Sciences
I have a patent pending on cytokines and type 1 interferons. I have multiple patents on antigen specific tolerance.
NONE
NONE
Commercial Novartis, Atreca, Tolerion, Teva, AbbVie, Bristol Myers Squibb, Gossamer, 180LS, TG Therapeutics, Atara Bio
NONE
NONE
NONE
Atara Bio, Novartis
NIH 2U01AI101984-06 Cooperative Study Group for Autoimmune Disease Prevention (U01)
NONE
NONE
Stock options and board membership in Atreca Board of Directors BioAtla
NONE
Tolerion Stock/Stock Options, Medical Equipment & Materials: Tolerion, Atreca, Adaptive
NONE
NONE
NONE
- From the LA County and University of Southern California General Hospital and Clinic (R.B.), Los Angeles; Kazan State Medical University (A.Y.), Russia; UCLA (J.E.), Los Angeles, CA; GRECC, VA Salt Lake, University of Utah (N.C.), Salt Lake City; and Stanford University (L.S.), Palo Alto, CA.
- Correspondence
Dr. Berkovich reginaberkovichmd{at}gmail.com
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Impaired T-cell migration to the CNS under fingolimod and dimethyl fumarateAmandine Mathias, Sylvain Perriot, Mathieu Canales et al.Neurology: Neuroimmunology & Neuroinflammation, October 11, 2017 -
Research
Effect of switching from natalizumab to moderate- vs high-efficacy DMT in clinical practiceCarrie M. Hersh, Haleigh Harris, Devon Conway et al.Neurology: Clinical Practice, February 12, 2020 -
Article
COVID-19 and MS disease-modifying therapiesJoseph R. Berger, Rachel Brandstadter, Amit Bar-Or et al.Neurology: Neuroimmunology & Neuroinflammation, May 15, 2020 -
Review
Lymphopenia and DMTs for relapsing forms of MSConsiderations for the treating neurologistEdward J. Fox, Guy J. Buckle, Barry Singer et al.Neurology: Clinical Practice, January 08, 2019